Table 4 MiRNA signature: controls vs. Intermediate-Risk group (Gleason = 7).

From: Role of circulating MicroRNAs in prostate cancer diagnosis and risk stratification in the MCC Spain study

miRNA

TMM

cases*

TMM

controls*

log2(FC)

Fold change*

Odds ratio

(95% CI)**

P**

Odds ratio

(95% CI)***

P***

miR-139-5p

−4.093

−4.154

0.061

1.043

0.57(0.36–0.90)

0.017

0.53 (0.33–0.85)

0.009

miR-141-3p

−5.777

−5.408

−0.369

0.774

0.69(0.47–1.02)

0.060

0.67 (0.45–1.00)

0.052

miR-145-5p

−1.758

−2.306

0.548

1.462

1.71(0.92–3.17)

0.089

1.96 (1.02–3.78)

0.043

miR-150-5p

−0.233

0.316

−0.549

0.683

0.66(0.40–1.11)

0.115

0.60 (0.35–1.05)

0.073

miR-182-5p

−6.107

−5.728

−0.379

0.769

0.72(0.48–1.08)

0.114

0.73 (0.48–1.12)

0.148

miR-199a-5p

−3.431

−4.267

0.836

1.785

2.12(1.19–3.77)

0.011

1.93 (1.04–3.59)

0.038

miR-26b-5p

0.064

−0.128

0.192

1.142

3.31(1.09–10.10)

0.035

3.84 (1.14–12.90)

0.030

miR-93-5p

1.471

1.421

0.050

1.035

2.37(0.93–6.05)

0.072

2.27 (0.82–6.26)

0.114

miR-96-5p

−6.400

−5.761

−0.639

0.642

0.71(0.49–1.02)

0.065

0.73 (0.49–1.08)

0.112

  1. Notes:.
  2. • TMM (Trimmed Mean of M-values): Method used for miRNA expression normalization.
  3. • Fold change (FC): Ratio of expression between cases and controls (FC > 1 indicates overexpression; FC < 1 indicates underexpression). log₂(FC) is the base-2 logarithmic transformation of FC.
  4. • Crude (unadjusted) vs. Adjusted (** and ***): The unadjusted model does not control for any confounders; the second model is adjusted for all miRNAs included in the final set; the third model also adjusts for age, BMI, educational level, socioeconomic status, and smoking.
Back to article page